Insider Selling: Lantheus Holdings, Inc. (LNTH) CEO Sells 10,000 Shares of Stock
Lantheus Holdings, Inc. (NASDAQ:LNTH) CEO Mary Anne Heino sold 10,000 shares of the firm’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $18.05, for a total value of $180,500.00. Following the transaction, the chief executive officer now directly owns 592,468 shares of the company’s stock, valued at approximately $10,694,047.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Mary Anne Heino also recently made the following trade(s):
- On Monday, June 12th, Mary Anne Heino sold 10,000 shares of Lantheus Holdings stock. The shares were sold at an average price of $15.39, for a total value of $153,900.00.
Shares of Lantheus Holdings, Inc. (NASDAQ LNTH) opened at 18.90 on Wednesday. The company has a 50-day moving average price of $17.54 and a 200 day moving average price of $13.87. The company has a market capitalization of $705.92 million, a P/E ratio of 25.82 and a beta of 0.91. Lantheus Holdings, Inc. has a 12-month low of $5.21 and a 12-month high of $20.45.
Lantheus Holdings (NASDAQ:LNTH) last issued its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.42 EPS for the quarter, beating the consensus estimate of $0.24 by $0.18. Lantheus Holdings had a negative return on equity of 37.47% and a net margin of 8.44%. The company had revenue of $88.83 million for the quarter, compared to analyst estimates of $80.56 million. During the same period last year, the company earned $0.24 earnings per share. Lantheus Holdings’s quarterly revenue was up 13.9% compared to the same quarter last year. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post $1.07 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/09/insider-selling-lantheus-holdings-inc-lnth-ceo-sells-10000-shares-of-stock-updated-updated-updated.html.
Several equities analysts have commented on LNTH shares. Jefferies Group LLC raised their price objective on Lantheus Holdings from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, May 3rd. Zacks Investment Research lowered Lantheus Holdings from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Credit Suisse Group lifted their price target on Lantheus Holdings from $14.00 to $19.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. Finally, Cantor Fitzgerald started coverage on Lantheus Holdings in a research report on Monday, July 17th. They issued an “overweight” rating and a $22.00 price target for the company. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $18.60.
Hedge funds have recently modified their holdings of the stock. Alambic Investment Management L.P. raised its stake in shares of Lantheus Holdings by 43.2% in the first quarter. Alambic Investment Management L.P. now owns 95,832 shares of the medical equipment provider’s stock valued at $1,198,000 after buying an additional 28,900 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Lantheus Holdings during the first quarter valued at approximately $332,000. Parametric Portfolio Associates LLC raised its stake in shares of Lantheus Holdings by 28.9% in the first quarter. Parametric Portfolio Associates LLC now owns 22,530 shares of the medical equipment provider’s stock valued at $282,000 after buying an additional 5,058 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Lantheus Holdings by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock worth $856,000 after buying an additional 4,084 shares in the last quarter. Finally, Algert Global LLC purchased a new stake in shares of Lantheus Holdings during the first quarter worth about $357,000. 66.32% of the stock is currently owned by institutional investors.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Stock Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related stocks with our FREE daily email newsletter.